| Literature DB >> 27110573 |
Eleonora Baldissarro1, Roberto Aquilani2, Federica Boschi3, Paola Baiardi4, Paolo Iadarola2, Marco Fumagalli2, Evasio Pasini5, Manuela Verri2, Maurizia Dossena2, Arianna Gambino6, Sharon Cammisuli1, Simona Viglio7.
Abstract
It is not known whether postsurgery systemic inflammation and plasma amino acid abnormalities are still present during rehabilitation of individuals after elective hip arthroplasty (EHA). Sixty subjects (36 females; age 66.58 ± 8.37 years) were randomized to receive 14-day oral EAAs (8 g/day) or a placebo (maltodextrin). At admission to and discharge from the rehabilitation center, serum C-reactive protein (CRP) and venous plasma amino acid concentrations were determined. Post-EHA hip function was evaluated by Harris hip score (HHS) test. Ten matched healthy subjects served as controls. At baseline, all patients had high CRP levels, considerable reduction in several amino acids, and severely reduced hip function (HHS 40.78 ± 2.70 scores). After treatment, inflammation decreased both in the EAA group and in the placebo group. Only EAA patients significantly improved their levels of glycine, alanine, tyrosine, and total amino acids. In addition, they enhanced the rate of hip function recovery (HHS) (from baseline 41.8 ± 1.15 to 76.37 ± 6.6 versus baseline 39.78 ± 4.89 to 70.0 ± 7.1 in placebo one; p = 0.006). The study documents the persistence of inflammation and plasma amino acid abnormalities in post-EHA rehabilitation phase. EAAs enhance hip function retrieval and improve plasma amino acid abnormalities.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27110573 PMCID: PMC4823478 DOI: 10.1155/2016/9318329
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Demographic, anthropometric variables, nutritional intakes, biohumoral variables, and clinical-functional test of the entire patient population at admission to our rehab institute.
| Admission | Discharge |
| |
|---|---|---|---|
| Age (yrs) | 66.58 ± 8.37 | — | n.s. |
| M/F | 24/36 | — | n.s. |
| Body weight (kg) | 74.5 ± 14.5 | 73.9 ± 14.5 | n.s. |
| Body mass index (BMI) kg/m2 | 26.6 ± 4.1 | 26.5 ± 4.05 | n.s. |
| Time from index event (days) | 17.05 ± 1.12 | 34 ± 2.0 | n.s. |
| Length of stay (days) | 16.9 ± 1.0 | — | n.s. |
|
| |||
| Energy (kcal) | 2123 ± 325 | — | n.s. |
| kcal/kg | 28.5 ± 2.7 | — | n.s. |
| Carbohydrates (g/kg) | 3.9 ± 0.6 | — | n.s. |
| Proteins (g/kg) | 1.01 ± 0.3 | — | n.s. |
| Lipids (g/kg) | 1.01 ± 0.35 | — | n.s. |
|
| |||
| Glucose (mg/dL; n.v. | 84.6 ± 14.8 | 83.4 ± 12 | n.s. |
| Urea (mg/dL; n.v. | 35.1 ± 8.8 | 34.6 ± 7.7 | n.s. |
| Creatinine (mg/dL; n.v. | 0.74 ± 0.09 | 0.76 ± 0.12 | n.s. |
| Erythrocyte sedimentation rate (mm/1 hr; n.v. | 47.9 ± 25.9 | 40.4 ± 24.9 | n.s. |
| C-reactive protein (mg/dL; n.v. | 20.4 ± 19.6 | 8.21 ± 11.1 | n.s. |
| Hemoglobin (g/dL; n.v. | 10.4 ± 1.09 | 11.3 ± 1.09 | <0.02 |
| Iron ( | 40.4 ± 19 | 48.5 ± 17.7 | n.s. |
| Ferritin (ng/mL; n.v. | 257.4 ± 201.8 | 235 ± 182 | n.s. |
| Transferrin (mg/dL; n.v. | 203 ± 32 | 209 ± 30.6 | n.s. |
| Albumin (g/dL; n.v. | 3.55 ± 0.37 | 3.79 ± 0.33 | n.s. |
| Total protein (g/dL; n.v. | 6.24 ± 0.50 | 6.49 ± 0.47 | n.s. |
|
| 6.96 ± 1.28 | 5.49 ± 0.71 | n.s. |
|
| 12.45 ± 2.2 | 11.33 ± 2.06 | n.s. |
|
| |||
| Harris hip score | 40.78 ± 2.70 | 73.15 ± 7.52 | <0.0001 |
Data are expressed as mean ± standard deviation. Normal value.
Statistical analysis: paired t-test; n.s. = not significant.
#Wilcoxon signed rank test.
Venous plasma concentration (μmol/L) of amino acids measured in the entire patient population both at admission to and discharge from our rehab institute. For comparison, plasma amino acid levels in healthy subjects were reported.
| Healthy subjects ( | Patients ( | ||
|---|---|---|---|
| Admission | Discharge ( | ||
| Aspartate | 19 ± 9 | 21.9 ± 11.6 | 16 ± 9 |
| Glutamate | 95 ± 63 | 154 ± 93 | 128.6 ± 32 |
| Asparagine | 23 ± 9 | 19.7 ± 9.2 | 19.1 ± 11.2■ |
| Serine | 111 ± 31 | 65.8 ± 33○ | 50.8 ± 15.2○ |
| Glutamine | 483 ± 100 | 99.4 ± 32○ | 120.5 ± 28#○ |
| Histidine | 62 ± 12 | 68.6 ± 35.6 | 66.5 ± 24 |
| Glycine | 227 ± 80 | 143 ± 107 | 122 ± 23.5○ |
| Threonine | 118 ± 32 | 198 ± 104 | 173.7 ± 62.9 |
| Citrulline | 8.5 ± 2.1 | 19.6 ± 9.4 | 22.3 ± 9.7# |
| 3-Methylhistidine | 3.24 ± 0.87 | 4.86 ± 2.5 | 6.4 ± 4.1 |
| Alanine | 385 ± 92 | 307 ± 82 | 298 ± 89■ |
| Arginine | 62 ± 20 | 138 ± 60■ | 160 ± 81.40■ |
| Tyrosine | 65 ± 14 | 47 ± 16■ | 48.7 ± 16.7 |
| Cysteine | — | 48 ± 28.5 | 50 ± 16.8 |
| Valine | 249 ± 58 | 202 ± 74 | 203 ± 69 |
| Methionine | 21.5 ± 5.2 | 24.8 ± 15.7 | 18.1 ± 10 |
| Tryptophan | 70 ± 33 | 70.3 ± 33 | 59 ± 28 |
| Phenylalanine | 70 ± 30 | 51.20 ± 20 | 50.5 ± 20 |
| Isoleucine | 68 ± 16 | 63.6 ± 26 | 61 ± 21 |
| Leucine | 128 ± 28 | 105 ± 49 | 102 ± 35.8 |
| Lysine | 180 ± 36 | 107 ± 57 | 96 ± 21○ |
| Total AAs | 2493.5 ± 652.4 | 1960 ± 890.5 | 1872 ± 628.3■ |
| Total EAAs | 904.5 ± 238 | 822 ± 379 | 821.5 ± 268 |
Data are expressed as mean ± standard deviation.
Statistical analysis:
(a) unpaired t-test between patients and healthy subjects at both admission to and discharge from rehab institute; ○ p < 0.001; ■ p < 0.02; p < 0.05;
(b) paired t-test between patient discharge and admission: # p < 0.05.
Demographic, anthropometric variables, nutritional intakes, biohumoral variables, and clinical-functional test of the admitted patients after randomization.
| Placebo | EAAs |
| |
|---|---|---|---|
| Age (yrs)† | 65.6 ± 9.50 | 67.9 ± 7.3 | 0.2 |
| M/F‡ | 10/20 | 14/16 | 0.3 |
| Body weight (kg)† | 73.0 ± 12.2 | 75.9 ± 15.9 | 0.3 |
| Body mass index (BMI) kg/m2 † | 27.5 ± 3.9 | 29.8 ± 4.2 | 0.07 |
| Time from index event (days)† | 16.0 ± 1.1 | 17.9 ± 1.2 | <0.05 |
| Length of stay (days)† | 15.2 ± 1.2 | 17 ± 0.8 | <0.08 |
|
| |||
| Energy (kcal) | 1980 ± 285 | 2210 ± 441 | 0.3 |
| kcal/kg | 27.1 ± 2.1 | 29.1 ± 4.33 | 0.5 |
| Carbohydrates (g/kg) | 3.7 ± 0.4 | 4.1 ± 0.8 | 0.8 |
| Proteins (g/kg) | 1.1 ± 0.4 | 0.9 ± 0.2 | 0.6 |
| Lipids (g/kg) | 0.95 ± 0.25 | 1.15 ± 0.40 | 0.8 |
|
| |||
| Glucose (mg/dL; n.v. | 82.2 ± 16.5 | 87.0 ± 15.5 | 0.6 |
| Urea (mg/dL; n.v. | 34.7 ± 10.9 | 35.7 ± 8.1 | 0.2 |
| Creatinine (mg/dL; n.v. | 0.73 ± 0.08 | 0.74 ± 0.09 | 0.2 |
| Erythrocyte sedimentation rate (mm/1 hr; n.v. | 45.3 ± 24.2 | 49.4 ± 28 | 0.4 |
| C-reactive protein (mg/dL; n.v. | 16.4 ± 11.7 | 20.5 ± 18.1 | 0.5 |
| Hemoglobin (g/dL; n.v. | 10.4 ± 1.2 | 10.5 ± 0.96 | 0.1 |
| Ferritin (ng/mL; n.v. | 206.7 ± 166 | 288 ± 212 | 0.3 |
| Transferrin (mg/dL; n.v. | 215 ± 34 | 191 ± 29 | <0.04 |
| Albumin (g/dL; n.v. | 3.62 ± 0 | 3.57 ± 0 | <0.07 |
| Total protein (g/dL; n.v. | 6.37 ± 0.51 | 6.1 ± 0.38 | <0.04 |
|
| 6.7 ± 1.1 | 6.97 ± 1.38 | 0.1 |
|
| 11.9 ± 2.5 | 11.1 ± 2.4 | 0.1 |
|
| |||
| Harris hip score | 39.78 ± 4.89 | 41.8 ± 1.15 | 0.9 |
Data are expressed as mean ± standard deviation. Normal value.
Statistical analysis:
(a) †unpaired t-test;
(b) ‡Chi-square test;
(c) #Mann-Whitney test.
Plasma amino acid levels (μmol/L) in stroke placebo and treated subgroups at both admission and discharge.
| Amino acid | Placebo ( | EAAs ( | Trend over time (interaction; | ||
|---|---|---|---|---|---|
| Admission | Discharge | Admission | Discharge ( | ||
| Aspartate | 20.5 ± 8.2 | 14.3 ± 5.9 | 24.5 ± 16.7 | 11.1 ± 7.8 | =0.6 |
| Glutamate | 177 ± 100 | 129.6 ± 19.6 | 143 ± 116 | 127.6 ± 45 | =0.8 |
| Asparagine | 21.5 ± 10.6 | 20.5 ± 11.9 | 16.7 ± 6.6 | 17.7 ± 10.5 | =0.5 |
| Serine | 72 ± 43 | 51.4 ± 20 | 64.5 ± 24 | 50.2 ± 10.3 | =0.9 |
| Glutamine | 97 ± 33 | 124.3 ± 21 | 104.2 ± 31 | 128.4 ± 33 | =0.7 |
| Histidine | 74.2 ± 33 | 72.6 ± 17 | 58.2 ± 40.1 | 64.0 ± 31.3 | =0.8 |
| Glycine | 157 ± 125 | 121 ± 24.4 | 118 ± 60 | 130 ± 22.5 | =0.001 |
| Threonine | 223 ± 96 | 177 ± 61.7 | 151.3 ± 110 | 170.3 ± 64 | =0.1 |
| Citrulline | 20.5 ± 9.9 | 23.1 ± 10 | 19 ± 9.5 | 21.5 ± 9.4 | =0.6 |
| 3-Methylhistidine | 5.5 ± 2.9 | 8.3 ± 6.2 | 3.78 ± 1.22 | 4.5 ± 1.9 | =0.7 |
| Alanine | 356 ± 195 | 312 ± 65 | 216 ± 119 | 284 ± 112 | =0.02 |
| Arginine | 136 ± 67.7 | 200 ± 117 | 144.2 ± 51 | 119 ± 45 | =0.03 |
| Tyrosine | 55.3 ± 27 | 49.3 ± 16.4 | 43.7 ± 14.9 | 48.0 ± 17 | =0.05 |
| Cysteine | 55.1 ± 29.6 | 55.2 ± 19 | 34.4 ± 22.3 | 45.1 ± 14.5 | =0.05 |
| Valine | 219 ± 71 | 214.5 ± 59 | 180.4 ± 77 | 193.1 ± 80 | =0.8 |
| Methionine | 28.6 ± 16 | 19.7 ± 10.4 | 17.6 ± 14.4 | 16.5 ± 9.5 | =0.6 |
| Tryptophan | 76.4 ± 28 | 62 ± 14.6 | 59 ± 40.4 | 56 ± 41.5 | =0.8 |
| Phenylalanine | 54.4 ± 21 | 53.3 ± 16.6 | 45 ± 17 | 47.6 ± 24 | =0.9 |
| Isoleucine | 66.5 ± 23 | 66.3 ± 20 | 62.1 ± 33 | 55.2 ± 21.8 | =0.8 |
| Leucine | 113 ± 46 | 108 ± 36 | 98.1 ± 56 | 95.2 ± 36 | =0.9 |
| Lysine | 109 ± 52 | 97 ± 26.6 | 95.1 ± 51 | 94.4 ± 15.5 | =0.8 |
| Total AAs | 2137 ± 1004 | 1979 ± 603 | 1699 ± 913 | 1833 ± 658.5 | =0.02 |
| Total EAAs | 890 ± 353 | 798 ± 247 | 709 ± 400 | 728 ± 293 | =0.05 |
EAAs = essential amino acids.
Data are reported as mean ± standard deviation.
Statistical analysis: repeated measures analysis of variance.
Trend over time: interaction differences in trends between groups.
Figure 1Time courses of improvements of clinical-functional test in the two postsurgery subgroups. The plot shows the superiority of essential amino acids in enhancing hip function recovery.
Changes over time of clinical-functional test Harris hip score (HHS) in both placebo and EAA groups.
| Placebo | EAAs |
| |||
|---|---|---|---|---|---|
| Admission | Discharge | Admission | Discharge ( | ||
| Harris hip score | 39.78 ± 4.89 | 70 ± 7.1 | 41.8 ± 1.15 | 76.37 ± 6.6 | 0.006 |
|
| |||||
| Pain | 18.7 ± 3.4 | 32.4 ± 6.2 | 20 ± 0 | 39.2 ± 5.59 | 0.01 |
| Support | 1.73 ± 0.69 | 2.7 ± 0.45 | 1.93 ± 0.37 | 2.73 ± 0.45 | 0.7 |
| Limp | 4.83 ± 0.91 | 8.5 ± 1.38 | 5 ± 0 | 8.72 ± 1.53 | 0.5 |
| Distance | 1.93 ± 0.36 | 8 ± 0 | 2.1 ± 0.55 | 8 ± 0 | 0.8 |
| Sitting | 3.13 ± 0.5 | 4.33 ± 0.96 | 3 ± 0 | 4.03 ± 1.01 | 0.7 |
| Public transportation | 0 | 0.56 ± 0.5 | 0 | 0.58 ± 0.509 | 0.9 |
| Stairs | 0 | 2 ± 0 | 0 | 2 ± 0 | — |
| Shoe/socks | 1.86 ± 0.50 | 3.06 ± 1.01 | 2 ± 0 | 2.69 ± 0.97 | 0.3 |
| Deformity | 4 ± 0 | 4 ± 0 | 4 ± 0 | 4 ± 0 | — |
| ROM | 3.51 ± 0.35 | 4.43 ± 0.33 | 3.58 ± 0.387 | 4.44 ± 0.25 | 0.9 |
Statistical analysis: Kruskal-Wallis test.
Level of significance set at p < 0.05.